Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06575933 · ClinicalTrials.gov registry record · Phase 1
A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06575933 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 28 participants.
The verdict
NCT06575933, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers are testing if digoxin and midazolam levels in the body are different when digoxin and midazolam are given with or without calderasib.
Interventions
- DRUG Midazolam
- DRUG Calderasib
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2024-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06575933
The ClinicalTrials.gov registry entry for NCT06575933 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Midazolam is the first listed.
NCT06575933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06575933 about?
NCT06575933 is a clinical study titled "A Study of Calderasib (MK-1084) With Midazolam and Digoxin in Healthy Participants (MK-1084-009)". The goal of the study is to see what happens to levels of midazolam and digoxin in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to midazolam and digoxin in the body when it is given with and without another medicine called calderasib. Researchers a...
What is the current status of trial NCT06575933?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-09-03. Estimated completion is 2024-10-28.
What interventions are being tested in trial NCT06575933?
The interventions under investigation include: Midazolam (DRUG), Calderasib (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT06575933?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.